Both in vitro and in vivo data demonstrated that inhibition of CLK2 reversed platinum resistance of OC cells, and, when combined with a PARP inhibitor, synergistically suppressed tumor growth in the BRCA1WT PDX model but not the BRCA1MUT PDX model. Here, CLK2 is linked to neoplasm.